NCT03016871View on ClinicalTrials.gov

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

January 30, 2024

Study Completion Date

April 30, 2026

Conditions
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
DRUG

Carboplatin

Given IV

DRUG

Etoposide

Given IV

DRUG

Ifosfamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (4)

77030

M D Anderson Cancer Center, Houston

91010

City of Hope Medical Center, Duarte

98109

Fred Hutchinson Cancer Research Center, Seattle

06520

Yale University, New Haven

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER